Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Signs Novartis to LEADS License

NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option to extend to two, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. While Compugen would not disclose financial details of the arrangement, a company spokesperson revealed that it was in the “multi-million dollar per year” range.  

“Compugen will analyze both EST and genomic databases to create for Novartis a reliable representation of transcriptomes of various organisms,” Mor Amitai, CEO of Compugen, said in a statement.

The LEADS bioinformatics platform incorporates genomics and proteomics tools and public and proprietary databases.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.